Original price was: $79.00.$67.15Current price is: $67.15.
View certificate of analysis — lot [LOT_PENDING — Frank to supply] →
Dual-peptide research blend (CJC-1295 no DAC + Ipamorelin) supplied for GHRH-analog and secretagogue-pathway research models.
CAS Number: 863288-34-0 (CJC-1295 no DAC) / 170851-70-4 (Ipamorelin)
Form: Lyophilized Powder Blend
Quantity: 10mg total
Purity: ≥99% (HPLC verified)
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂ (CJC-1295 no DAC) / C₃₈H₄₉N₉O₅ (Ipamorelin)
Molecular Weight: 3,367.9 g/mol (CJC-1295 no DAC) / 711.9 g/mol (Ipamorelin)
Storage: −20°C recommended
Stability: 24+ months lyophilized
Category: Research Compounds
Use: Not for human or animal use. Research laboratory use only.
In stock
All major credit cards accepted
CJC-1295 + Ipamorelin (no DAC) is a research blend combining two mechanistically distinct growth-hormone-axis peptides: CJC-1295, a modified growth-hormone-releasing hormone GHRH(1-29) analog, and ipamorelin, a selective growth hormone secretagogue of the GHRP family. The two components act at separate receptor populations on pituitary somatotrophs — the GHRH receptor (GHRHR) and the growth hormone secretagogue receptor (GHS-R1a), respectively. The “no DAC” designation denotes the modified GRF(1-29) form without the drug-affinity-complex modification. This combination is supplied as a reference material for laboratory studies of dual-receptor somatotroph signaling and comparative GHRH-analog / GHRP pharmacology, distributed strictly for in vitro and preclinical investigation by qualified researchers. Not for human or animal use. Research laboratory use only.
All compounds referenced are supplied for laboratory and research applications only and are not for human consumption.
This blend pairs a growth-hormone-releasing hormone (GHRH) analog with a growth-hormone-releasing peptide (GHRP) — two classes that engage separate receptors on the pituitary somatotroph. CJC-1295 is a synthetic analog of GHRH(1-29) carrying amino-acid substitutions that increase peptide stability; Teichman and colleagues characterized CJC-1295 as a long-acting GHRH analog in research on the somatotropic axis.1 Work in GHRH-receptor knockout models has been used to examine the receptor-dependence of GHRH-analog activity,2 and additional research has investigated how continuous GHRH-analog exposure interacts with the pulsatile architecture of growth-hormone secretion.3 The ipamorelin component acts at the growth hormone secretagogue receptor (GHS-R1a) rather than the GHRH receptor; it was first characterized by Raun and colleagues as the first selective growth-hormone secretagogue.4 Because the two peptides engage the GHRHR and GHS-R1a like their respective parent classes, the blend is studied as a model system for investigating convergent somatotroph signaling and receptor-crosstalk questions. All references to CJC-1295 and ipamorelin here describe receptor pharmacology and preclinical or controlled research contexts only; the material is a laboratory reagent, and no clinical, human, or veterinary use is described or implied.
Not for human or animal use. Research laboratory use only.
A professional platform for accessing research compounds with clarity, consistency, and research-first standards.
From sourcing to fulfillment, every step of our process is structured around clarity, consistency, and professional research standards.
Our platform is built to support efficient research workflows with organized categories, standardized product presentation, and simple reordering.
Every product is presented in formats designed for stability, professional handling, and alignment with laboratory environments.
4.8 Stars
Our approach prioritizes clarity, structure, and transparency. Each compound is presented with research-focused documentation, neutral communication, and consistent labeling to support scientific workflows.
We believe long-term trust is built through precision, not promotion.
